PMID- 24138944
OWN - NLM
STAT- MEDLINE
DCOM- 20140218
LR  - 20181202
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 37
IP  - 12
DP  - 2013 Dec
TI  - A phase I study of decitabine and rapamycin in relapsed/refractory AML.
PG  - 1622-7
LID - S0145-2126(13)00319-6 [pii]
LID - 10.1016/j.leukres.2013.09.002 [doi]
AB  - A phase I study utilizing decitabine (DAC) followed by the mammalian target of 
      rapamycin (mTOR) inhibitor, rapamycin, in patients with relapsed/refractory adult 
      AML was undertaken to assess safety and feasibility. Patients received DAC 
      20mg/m(2) intravenously daily for 5 days followed by rapamycin from day 6 to day 
      25 at doses of 2 mg, 4 mg, and 6 mg/day in a standard 3+3 dose escalation design. 
      Twelve patients completed treatment for safety evaluation. Maximum tolerated dose 
      (MTD) was not reached, and except for grade 3 mucositis in 4 patients, no other 
      significant unexpected non-hematologic toxicities have occurred indicating safety 
      of this regimen. This trial is registered at clinical trials.gov as NCT00861874.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Liesveld, Jane L
AU  - Liesveld JL
AD  - Department of Medicine, Division of Hematology/Oncology, University of Rochester, 
      Rochester, NY 14642, United States. Electronic address: 
      jane_liesveld@urmc.rochester.edu.
FAU - O'Dwyer, Kristen
AU  - O'Dwyer K
FAU - Walker, Alison
AU  - Walker A
FAU - Becker, Michael W
AU  - Becker MW
FAU - Ifthikharuddin, J J
AU  - Ifthikharuddin JJ
FAU - Mulford, Deborah
AU  - Mulford D
FAU - Chen, Rui
AU  - Chen R
FAU - Bechelli, Jeremy
AU  - Bechelli J
FAU - Rosell, Karen
AU  - Rosell K
FAU - Minhajuddin, Mohammed
AU  - Minhajuddin M
FAU - Jordan, Craig T
AU  - Jordan CT
FAU - Phillips, Gordon L 2nd
AU  - Phillips GL 2nd
LA  - eng
SI  - ClinicalTrials.gov/NCT00861874
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130908
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Azacitidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Decitabine
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Routes
MH  - Drug Administration Schedule
MH  - *Drug Resistance, Neoplasm/drug effects
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/pathology
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Pilot Projects
MH  - Recurrence
MH  - Sirolimus/*administration & dosage/adverse effects
OTO - NOTNLM
OT  - AML
OT  - Decitabine
OT  - Phase I
OT  - Rapamycin
OT  - Refractory
OT  - Relapsed
EDAT- 2013/10/22 06:00
MHDA- 2014/02/19 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/07/02 00:00 [received]
PHST- 2013/08/31 00:00 [revised]
PHST- 2013/09/02 00:00 [accepted]
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/02/19 06:00 [medline]
AID - S0145-2126(13)00319-6 [pii]
AID - 10.1016/j.leukres.2013.09.002 [doi]
PST - ppublish
SO  - Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 
      Sep 8.